The antioxidant effects of ellagic acid (EA) and hesperidin (HES) against skeletal muscle ischemia/reperfusion injury (I/R) were performed. Hindlimb ischemia has been induced by tourniquet occlusion for 2 h on left hindlimb. At the end of ischemia, the tourniquate has been removed and initiated reperfusion for 2 h. EA (100 mg/kg) has been applied orally before ischemia/reperfusion in the EA + I/R group. HES (100 mg/kg) has been given orally in the HES + I/R group. The left gastrocnemius muscle has been harvested and stored immediately at −80 °C until assessed for the levels of MDA and antioxidant enzymes activities. MDA level has statistically increased in I/R group (p < 0.05) compared to other groups. The muscle tissue antioxidant enzymes activities were lower than the other groups in the I/R group (p < 0.05). EA and HES treatments significantly reversed the damage level in I/R, also activity of tissue SOD increased in the EA + I/R and HES + I/R groups.
16 June 2016 in Journal of Enzyme Inhibition and Medicinal Chemistry
In this study, we investigated the potential beneficial effects of quercetin on skeletal muscle ischemia reperfusion injury. Twenty-four Sprague–Dawley type rats were randomly divided into four groups. In the sham group, only gastrocnemius muscle were removed and given no quercetin. In ischemia group, all the femoral artery, vein and collaterals were occluded in the left hindlimb by applying tourniquate under general anaesthesia for three hours but reperfusion was not done. In the Quercetin + Ischemia reperfusion group, quercetin (200 mg kg−1 dose orally) was given during one-week reoperation and later ischemia reperfusion model was done. Finally, gastrocnemius muscle samples were removed to measure biochemical parameters. The biomarkers, MDA levels, SOD, CAT and GPx activities, were evaluated related to skeletal muscle ischemia reperfusion injury. MDA levels reduced and SOD, CAT and GPx activities increased significantly in Quercetin + Ischemia reperfusion group. Results clearly showed that Quercetin have a protective role against oxidative damage induced by ischemia reperfusion in rats.
Lichens are a unique group of organisms, which can produce compounds that are named secondary metabolites and rarely or are not produced in other organisms. Lichens possess pharmacological actions related to their secondary metabolites. Our knowledge of lichens and their pharmacological actions rapidly increases as new technologies and devices, which facilitate the investigation of the chemical profile and biological activities of lichens, are introduced and become more readily available. In addition, new methods and perspectives, as well as suggestions for pharmacological mechanisms, accumulate daily. Furthermore, lichen substances stand as a relatively untapped source of natural products. Accordingly, researchers investigate the pharmacological actions of lichen-derived material more frequently than it was in the past. This review focused on the pharmacological activities of lichens published in the last 11 years (2012-2022). Literature data obtained from WebOfScience and PubMed databases using related search keywords revealed that anti-genotoxicity, anticancer, and anti-microbial activity studies have constantly been conducted. More recently, immunomodulatory and inflammation-related studies took to the stage. Enzyme inhibition actions were popular as well. Our selection was based on the novelty and mechanistic insight that papers presented. Cite this article as: Karagöz Y, Öztürk Karagöz B. Lichens in pharmacological action: What happened in the last decade? Eurasian J Med., 2022;54(Suppl. 1), S195-S208.
Pharmacogenetics of Antidepressants: Overview of Dosing Strategies in Major Depressive Disorder Saja SAİD Gül ÖZBEY Therapeutic Use of Cannabinoids: Clinical Overview and Recent Updates Beril ALTUN The Xanthine Oxidase Inhibitory Activities of Natural-Based Compounds Targeting Gout Nurcan DEDEOĞLU The Relationship of Dementia and Diabetes Mehtap TUGRAK SAKARYA Rational Use of Drugs Dilan ÖZMEN ÖZGÜN Endocrine Therapy in Breast Cancer: Recent Advances in the Drugs Used Dilek AKSOY Strategies to Increase Solubility and Bioavailability of Drugs İrem ÇİNAR Emrah ÖZAKAR Rukiye SEVİNÇ ÖZAKAR Vesıcular Drug Delivery Systems Muhammet Enes ÖZMUTLU Rukiye SEVİNÇ ÖZAKAR Emrah ÖZAKAR Definition of Pharmacovigilance and Its Historical Development in the World and Türkiye Berna ÖZTÜRK KARAGÖZ